Curated News
By: NewsRamp Editorial Staff
August 05, 2026
VERAXA Advances VXA-222 Cancer Program and Expands Patent Portfolio
TLDR
- VERAXA advances VXA-222 to next stage, expanding its oncology pipeline and strengthening its position in the competitive cancer therapy market.
- VXA-222, a bispecific antibody-drug conjugate, completed discovery with OmniAb, moving to engineering and preclinical validation using VERAXA's proprietary technologies.
- This progress in developing targeted cancer therapies brings hope for more effective treatments and improved outcomes for patients with difficult-to-treat cancers.
- VERAXA now holds over 50 patents across 26 families in 14 countries, extending protection to at least 2047, showcasing a robust IP portfolio.
Impact - Why it Matters
This news matters because it signals meaningful progress in the development of novel cancer therapies. For patients and the medical community, VXA-222 represents a potential new treatment option for difficult-to-treat cancers. For investors, it demonstrates VERAXA's ability to execute on its pipeline and strengthen its intellectual property, which could enhance the company's competitive position and long-term value. The expansion of the patent portfolio also provides a moat that could protect future revenues.
Summary
VERAXA Biotech AG (NASDAQ: VRXA), a leader in designing novel cancer therapies, has announced a significant advancement in its oncology pipeline. The company's VXA-222 bispecific antibody-drug conjugate (bsADC) program has successfully completed the discovery phase and is now moving into the next stage of development. This milestone follows the completion of the discovery work with OmniAb, a collaboration that began in May 2025 (https://nnw.fm/nIprz). OmniAb delivered a portfolio of therapeutic antibody binders, and VERAXA will now engineer the final bispecific ADC candidate using its proprietary antibody engineering, linker, and conjugation technologies. Importantly, while VXA-222 does not rely on VERAXA's BiTAC platform, it is one of the company's more advanced development programs.
In parallel, VERAXA has expanded its intellectual property portfolio with its first BiTAC-related patent filings and additional patents covering conjugation chemistry, payloads, and antibody technologies. The company now holds more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries, with new applications expected to extend protection into at least 2047. This robust IP strategy supports VERAXA's diversified oncology pipeline, which includes bispecific antibody-drug conjugates, T-cell engagers, and engineered antibody formats targeting difficult-to-treat cancers.
For more details, read the full announcement at Read More>>. Investors can also visit the company's newsroom at https://nnw.fm/VRXA for the latest updates. This news is distributed by NetworkNewsWire, a specialized communications platform focused on financial news and content distribution, part of the Dynamic Brand Portfolio @ IBN.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, VERAXA Advances VXA-222 Cancer Program and Expands Patent Portfolio
